HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck

Executive Summary

Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category
Advertisement

Related Content

Schering Tries To Lower Merck HDL Agent Expectations, Without Razing JV
Schering Tries To Lower Merck HDL Agent Expectations, Without Razing JV
Merck delays Zocor/niacin combo
Merck delays Zocor/niacin combo
Schering Expects Earnings Decline In Second Half, Despite Solid Start To 2006
Schering Expects Earnings Decline In Second Half, Despite Solid Start To 2006
Vytorin Takes Low Road To Higher Ground: Lower LDL Is Key To Growth
Merck Expects Expedited Filing Of HDL-Cholesterol Drugs Using Existing Data
Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms
Merck/Schering Ezetimibe Deal Is Part Of Growing Ties Between Firms
Advertisement
UsernamePublicRestriction

Register

PS046759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel